Table 2 Summary of mean fractions (%) and standard deviations (in parentheses) of securin and Ki-67 immunopositive nuclei

From: Securin promotes the identification of favourable outcome in invasive breast cancer

 

Securin

Ki-67

All

6.1 (6.8)

15.0 (14.2)

 Ki-67, <10%

3.3 (4.1)

4.5 (2.6)

 Ki-67, ⩾10%

8.6 (7.3)

24.0 (14.0)

IDC

6.4 (6.9)

16.0 (14.8)

 Ki-67, <10%

3.5 (4.3)

4.8 (2.5)

 Ki-67, ⩾10%

8.5 (7.3)

24.5 (14.5)

  1. The results are based on all patients with invasive breast carcinoma (n=310) and on subgroups divided according to invasive ductal histology (IDC) and Ki-67 immunopositivity (low, <10%; high, ⩾10%).
Back to article page